At present, AD is defined by the presence of amyloid-beta (Aβ) and tau protein aggregates in the brain and is driven by multiple pathophysiological processes, from proteostatic abnormalities to inflammation, vascular disease, and metabolic dysfunction [2]. This evidence concerns the gene MAPT and Alzheimer disease.